Przewalskine






Names

    • Przewalskine

Attributes

  • Canonical SMILES

    CN1CCC2=C3[C@@H]1CC4=CC(=C(C=C4C3=C(C(=C2OC)OC)OC)OC)OC5=C(C=CC(=C5OC)C[C@@H]6C7=CC(=C8C(=C7CCN6C)OCO8)OC)OC

  • InChI

    InChI=1S/C42H48N2O10/c1-43-14-12-24-27(20-33(47-5)39-38(24)52-21-53-39)28(43)16-22-10-11-30(45-3)40(36(22)48-6)54-32-18-23-17-29-34-25(13-15-44(29)2)37(49-7)42(51-9)41(50-8)35(34)26(23)19-31(32)46-4/h10-11,18-20,28-29H,12-17,21H2,1-9H3/t28-,29+/m1/s1

  • Molecule Class: Alkaloids
  • TPSA: 98.78000000000002
  • #RotBonds: 11
  • MW: 740.8499999999999
  • HBD: 0
  • HBA: 12
  • logP: 6.791600000000006
  • Chemical Formula: C42H48N2O10


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. bufalina China 403123 Cai20170220

External Databases


References

  • Alkaloids isolated from Tabernaemontana bufalina display xanthine oxidase inhibitory activity. Phytochemistry, 2019 (PMID 31302343).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Xanthine oxidase inhibitory

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -5.36
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Non-Absorbed
    Madin-Darby Canine Kidney 46.68
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 6786.23
    Distribution Blood-Brain Barrier (Central Nervous System) -2.73
    Blood-Brain Barrier Non-Penetrable
    Fraction Unbound (Human) 0.56
    Plasma Protein Binding 36.89
    Steady State Volume of Distribution 0.82
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 10.54
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Toxic
    Bee Toxic
    Bioconcentration Factor -161.4
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.11
    Liver Injury II Safe
    hERG Blockers Toxic
    Daphnia Maga 6.06
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Toxic
    T. Pyriformis -12319730.14
    Rat (Acute) 2.73
    Rat (Chronic Oral) 0.94
    Fathead Minnow 15556.68
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Toxic
    General Properties Boiling Point 1381539.4
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 4.42
    Log(P) 4.82
    Log S -4.28
    Log(Vapor Pressure) -45453.09
    Melting Point 164.42
    pKa Acid -294.53
    pKa Basic 10.15